FY2027 EPS Forecast for Omnicell Decreased by Analyst

Omnicell, Inc. (NASDAQ:OMCL) – Analysts at Zacks Research lowered their FY2027 EPS estimates for shares of Omnicell in a research note issued on Wednesday, February 26th. Zacks Research analyst R. Department now expects that the company will earn $1.22 per share for the year, down from their prior estimate of $1.36. The consensus estimate for Omnicell’s current full-year earnings is $1.09 per share.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%.

Several other research analysts have also weighed in on OMCL. Benchmark restated a “buy” rating and set a $62.00 price objective on shares of Omnicell in a research note on Tuesday, February 4th. Bank of America cut their target price on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research note on Monday, January 6th. Wells Fargo & Company cut their target price on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. StockNews.com cut shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Tuesday, December 10th. Finally, JPMorgan Chase & Co. upped their price target on shares of Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a research note on Thursday, November 21st. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $52.33.

Omnicell Stock Performance

OMCL opened at $38.06 on Friday. The business’s 50-day moving average price is $42.39 and its two-hundred day moving average price is $43.81. Omnicell has a 1 year low of $25.12 and a 1 year high of $55.74. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. The company has a market capitalization of $1.76 billion, a price-to-earnings ratio of 140.97, a P/E/G ratio of 7.53 and a beta of 0.78.

Insider Buying and Selling at Omnicell

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of the company’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total value of $567,600.00. Following the completion of the transaction, the director now owns 58,427 shares of the company’s stock, valued at $2,763,597.10. This represents a 17.04 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 2.64% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in OMCL. Creative Planning grew its holdings in Omnicell by 23.1% during the 3rd quarter. Creative Planning now owns 11,667 shares of the company’s stock worth $509,000 after acquiring an additional 2,188 shares during the last quarter. Roubaix Capital LLC acquired a new position in shares of Omnicell during the third quarter worth $1,851,000. 1620 Investment Advisors Inc. increased its holdings in Omnicell by 230.1% in the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock valued at $96,000 after purchasing an additional 1,542 shares during the period. Rice Hall James & Associates LLC bought a new position in Omnicell during the 3rd quarter worth $2,723,000. Finally, QRG Capital Management Inc. acquired a new position in Omnicell during the 3rd quarter worth about $231,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.